Liquid Biopsy Market Set to Hit $17.8B by 2033 as Multi-Omics Race Intensifies

Liquid Biopsy Products Product Definition

Liquid biopsy products are molecular diagnostic tools that analyze body fluids such as blood and urine to detect tumor-associated biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes. These platforms typically follow a workflow encompassing sample collection, plasma separation, target molecule extraction, and high-sensitivity analytical detection, with core reliance on advanced technologies such as digital PCR (ddPCR) and next-generation sequencing (NGS). Compared with traditional tissue biopsy, liquid biopsy offers minimally invasive or non-invasive sampling, repeatability, and the ability to dynamically capture tumor evolution, providing a more comprehensive view of tumor heterogeneity. This is particularly valuable for patients with difficult-to-access tissue or those requiring long-term monitoring. Product formats include in vitro diagnostic (IVD) kits, laboratory-developed testing (LDT) services, and supporting detection equipment coupled with bioinformatics analysis systems, forming an integrated “reagents–instruments–data analysis” industry ecosystem.

Clinically, liquid biopsy applications are expanding from adjunctive diagnostics toward precision therapy guidance and full-cycle disease management. Its most established use is in guiding targeted therapies, where detection of key mutations in genes such as EGFR and KRAS informs individualized treatment decisions. In efficacy evaluation and minimal residual disease (MRD) monitoring, liquid biopsy enables dynamic tracking of ctDNA levels, offering early warnings of disease progression or relapse. Multi-cancer early detection (MCED) represents a frontier direction, extending liquid biopsy into early diagnosis, although further validation is needed to optimize sensitivity and specificity for large-scale clinical implementation.

Global Cancer Incidence and Mortality Figures and Facts

Global cancer burden in 2022 remains substantial, with the International Agency for Research on Cancer (IARC) reporting 19.97 million new cases and 9.74 million deaths worldwide, including 5.43 million male and 4.31 million female fatalities. Lung cancer ranked first in incidence among all malignancies (12.4%), followed by female breast cancer (11.6%), colorectal cancer (9.6%), prostate cancer (7.3%), and stomach cancer (4.9%). Lung cancer also accounted for the highest mortality globally, with 1.82 million deaths (18.7%), followed by colorectal cancer (9.3%), liver cancer (7.8%), female breast cancer (6.9%), and stomach cancer (6.8%).

Analysis of 36 cancer types in 2022, including incidence, mortality, age-standardized rates (ASR), and cumulative risk before age 75 (CMS), indicates that males have a slightly higher cumulative risk of developing cancer before age 75 compared to females (21.8% vs. 18.5%), suggesting that roughly 1 in 5 individuals will be diagnosed with cancer in their lifetime. The cumulative risk of cancer death before age 75 is significantly higher in males than females (11.4% vs. 7.97%), implying that 1 in 8 men and 1 in 12 women will die of cancer. Among males, the most common malignancies are lung (15.3%), prostate (14.2%), colorectal (10.4%), stomach (6.1%), and liver cancers (5.8%), with lung cancer the leading cause of death (22.7%), followed by liver (9.6%), colorectal (9.2%), stomach (7.9%), and prostate cancers (7.3%). Among females, breast cancer is most prevalent (23.8%), followed by lung (9.4%), colorectal (8.9%), cervical (6.8%), and thyroid cancers (6.4%). Breast cancer accounts for the highest female mortality (15.4%), followed by lung (13.6%), colorectal (9.4%), cervical (8.1%), and liver cancers (5.5%). The top five malignancies account for more than 50% of new cases and deaths in both sexes, highlighting the heavy global cancer burden in 2022.

Regionally, Asia accounted for 49.2% of global new cancer cases and 56.1% of global cancer deaths, reflecting the region’s large population base (59.2% of the world population). Both Asia and Africa show cancer mortality exceeding incidence proportions (Asia: 56.1% vs. 49.2%; Africa: 7.8% vs. 5.9%), while Europe, the Americas, and Oceania have mortality below incidence proportions (Europe: 20.4% vs. 22.4%; Americas: 14.9% vs. 22.1%; Oceania: 0.8% vs. 1.4%). This disparity is largely driven by a high proportion of developing and underdeveloped populations in Asia and Africa, where limited healthcare resources result in delayed diagnosis and suboptimal treatment outcomes. Conversely, incidence and mortality in Europe, the Americas, and Oceania exceed their population shares (population shares: 9.6%, 13.1%, and 0.5%, respectively), indicating higher cancer risk in developed countries. Within each continent, significant regional differences exist in overall cancer incidence and mortality, as reflected in ASR and CMS metrics across 24 defined global regions.

Source: International Agency for Research on Cancer (2022 statistical study), 2026

Liquid Biopsy Product Industry Chain Analysis

Upstream supply for liquid biopsy products is built on critical inputs such as high-fidelity polymerases, highly specific antibodies, nucleic acid extraction and preservation reagents, and digital PCR–related components. Core suppliers are concentrated among global life science leaders including Thermo Fisher Scientific, F. Hoffmann-La Roche, QIAGEN, and Bio-Rad Laboratories. High-fidelity polymerases serve as a key material with extremely low error rates during DNA replication and amplification, effectively reducing false mutation signals and improving analytical accuracy. Production volumes remain limited, typically at gram- or milligram-scale per batch, while complex purification processes and strict activity requirements result in very high unit value, forming a typical “low-volume, high-value” supply characteristic.

Source: Secondary Sources, Expert Interviews and DIResearch, 2026

The technology pipeline of liquid biopsy is structured around core analytes including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, forming a multi-layered biomarker system. Enabling technologies such as next-generation sequencing (NGS), digital PCR (dPCR), and multi-omics integration provide the analytical backbone. Product formats are evolving from laboratory-developed tests (LDTs) toward standardized in vitro diagnostic (IVD) kits and integrated platforms. This evolution reflects a shift from single-marker detection to multi-marker integration, and from late-stage companion diagnostics toward early screening and minimal residual disease (MRD) monitoring.

Clinical application of liquid biopsy centers on dynamic biomarker monitoring, particularly ctDNA. Non-invasive and repeatable sampling enables real-time data generation for patient stratification, treatment response evaluation, and resistance mechanism analysis, improving the efficiency and success rates of oncology clinical trials, especially in targeted therapy and immunotherapy. Application boundaries are expanding from adjunctive diagnosis to early detection, with multi-cancer early detection (MCED) emerging as a key strategic focus due to its broad population coverage and significant market potential. Liquid biopsy technologies increasingly span the full continuum of drug development, including target discovery, patient selection, companion diagnostics, and longitudinal efficacy and resistance monitoring, supporting precision medicine and individualized treatment.

Global Liquid Biopsy Product Market Size Analysis

According to DIResearch＇s in-depth investigation and research, the global liquid biopsy product market will reach US$3.999 billion in 2026 and is projected to reach US$17.834 billion in 2033, with a compound annual growth rate (CAGR) of 23.81% (2026-2033). The global liquid biopsy market is shifting from early adoption to widespread application. North America holds 50%-55% of the market share and remains the leader. The Asia-Pacific region shows strong growth potential, driven by high cancer rates and government support for precision medicine and early screening.

Source: Secondary Sources, Expert Interviews and DIResearch, 2026

Competitive Landscape Analysis of Liquid Biopsy Products

Leading international companies such as Guardant Health, Qiagen, and Bio-Rad Laboratories leverage their mature sequencing platforms, global commercial networks, and large-scale clinical data accumulation to create high barriers to entry, giving them significant advantages in product standardization, testing accuracy, and market coverage. Companies like Biocartis, Sysmex Inostics, and Menarini Silicon Biosystems have developed differentiated competitive capabilities in specific technological areas, such as CTC capture, immunomics analysis, or specialized testing services, demonstrating strong competitive resilience in niche markets. Companies like Biocept, Cynvenio, MDxHealth, and Pathway Genomics, on the other hand, are relatively small in scale and have limited market influence, primarily relying on single technologies or regional markets to maintain their competitive position.

The liquid biopsy industry is highly driven by significant R&D investments. Core competitive factors revolve around enhancing detection sensitivity, advancing multi-gene analysis capabilities, and refining bioinformatics algorithms. Leading global players consistently allocate a substantial portion of their resources to R&D. They push the boundaries in areas like ctDNA detection, multi-cancer early detection (MCED), and minimal residual disease (MRD) monitoring. They reinforce their competitive advantage by accumulating extensive clinical trial data, solidifying their technological barriers. Chinese companies such as Burning Rock Biotech Limited, Beijing Genetron Health Technology Co., Ltd, Shanghai Kunyuan Biological Technology Co., Ltd, Berry Genomics, and Shanghai Huidu Medical Sciences Co., ltd have seen rapid R&D growth in recent years. They have made strides in NGS testing and building local data resources. However, they continue to face challenges in developing original technologies, achieving global clinical validation, and standardizing high-end products. Competition in the industry is shifting from a focus on individual product performance to a broader race driven by R&D capabilities, data resources, and technological platforms.

Bio Rad Laboratories

Headquarters: USA

Bio-Rad Laboratories, founded in 1952 and headquartered in Hercules, California, USA, is a leading global life sciences and clinical diagnostics company. The company's business is primarily divided into two segments: life sciences and clinical diagnostics. Life sciences provides instruments, reagents, and consumables covering nucleic acid, protein, and cell analysis, widely used in research institutions and the biopharmaceutical field; clinical diagnostics focuses on in vitro diagnostic systems, testing reagents, and quality control products, serving hospitals and medical laboratories. Technologically, Bio-Rad has deep expertise in PCR, digital PCR (ddPCR), immunoassay, and antibody development. Its high-sensitivity molecular detection technologies are of significant value in applications such as tumor mutation analysis and liquid biopsy. As of the end of 2025, the company had approximately 7,450 employees worldwide and generated approximately $2.58 billion in revenue.

Biocartis

Headquarters: Belgium

Founded in 2007 and headquartered in Mechelen, Belgium, Biocaritis is a company specializing in automated molecular diagnostic systems. Its core product, the Idylla platform, achieves fully automated "sample-to-result" testing through an integrated cartridge design, significantly reducing operational complexity and laboratory dependence. In liquid biopsy applications, the company provides rapid gene mutation detection solutions based on PCR technology, suitable for clinical settings such as hospitals. Overall, Biocaritis is positioned in the midstream of the industry chain, emphasizing equipment systems and ease of testing. Its products have advantages in point-of-care testing, but it has certain limitations compared to NGS-based companies in terms of throughput and multi-gene coverage. Its Idylla platform has been deployed in over 1,700 units globally, covering more than 70 countries, and testing for common tumor mutations such as EGFR, KRAS, and BRAF, with a single test taking approximately 90–150 minutes. The company's annual revenue in recent years has been approximately €50 million–70 million.

QIAGEN

Headquarters: Netherlands

Founded in 1984 and headquartered in Venlo, Netherlands, with an operations center in Hilden, Germany, QIAGEN is a leading global company in molecular diagnostics and life science tools. The company has built a complete solution system in the liquid biopsy field, covering sample collection, nucleic acid extraction, library construction, and data analysis, holding a particularly important position in key stages such as cfDNA extraction. As a typical upstream platform company, QIAGEN provides standardized reagents and equipment, serving a wide range of research institutions, clinical laboratories, and pharmaceutical companies. It possesses a strong technological foundation and channel advantages in the industry, making it a crucial infrastructure provider in the liquid biopsy industry chain. The company's revenue in 2025 was approximately $2.09 billion, with approximately 5,700 employees. Its liquid biopsy-related products cover the entire process of sample extraction, library construction, and analysis. Its cfDNA extraction reagents hold a significant market share.

Guardant Health

Headquarters: USA

Founded in 2012 and headquartered in Palo Alto, California, USA, Guardant Health is one of the most representative companies in the global liquid biopsy field. Based on ctDNA detection technology, the company has launched a series of products including Guardant360, GuardantOMNI, and Guardant Reveal, covering multiple application scenarios such as oncology medication guidance, minimal residual disease (MRD) monitoring, and early screening. Its business model is centered on clinical testing services, continuously strengthening its application value in precision medicine through large-scale clinical data accumulation and deep cooperation with pharmaceutical companies. Overall, Guardant Health is a leading downstream testing service provider with strong commercialization capabilities and market expansion advantages. In 2025, the company's revenue was approximately $982 million, with over 500,000 samples tested cumulatively. Its core product, Guardant360, is widely used in tumor gene testing. Its R&D expenditure has consistently exceeded 40%, with a focus on early screening (LUNAR) and MRD detection.

MDxHealth

MDxHealth Headquarters: USA

MDxHealth, founded in 2003 and headquartered in Liège, Belgium, is a company specializing in epigenetic molecular diagnostics. The company develops liquid biopsy products for urological tumors such as prostate cancer by detecting epigenetic markers such as DNA methylation, for disease risk assessment, auxiliary diagnosis, and recurrence monitoring. Unlike companies that focus on NGS as their core technology, MDxHealth adopts a "specific cancer type + specific biomarker" development strategy, possessing a high degree of clinical validation and specialization in its niche areas, but facing relative limitations in expanding to multiple cancer types and large-scale application. The company's revenue in 2025 was $108 million, primarily from prostate cancer detection products (such as ConfirmMDx and SelectMDx). Its detection is based on DNA methylation markers and has a high degree of clinical validation in the field of urological tumors.

Market Drivers For Liquid Biopsy Products

Statistics published in The Lancet show that the global and domestic cancer incidence rates continue to rise and are projected to continue increasing. By 2050, new cases are expected to surge to 30.5 million, and deaths to reach 18.6 million, representing increases of 60.7% and 74.5%, respectively. Against the backdrop of expanding clinical needs for precision medicine and full-cycle cancer management, non-invasive and repeatable liquid biopsies effectively compensate for the shortcomings of traditional tissue biopsies, and their application value in companion diagnostics, MRD monitoring, and early cancer screening continues to stand out. China's "Healthy China 2030" strategy lists early cancer diagnosis and treatment and precision medicine as core tasks. The NMPA (National Medical Products Administration) continues to optimize the medical device approval process, accelerating the approval and market launch of liquid biopsy products (such as early cancer screening and MRD monitoring kits) through innovative green channels. Simultaneously, many regions have included mature companion diagnostic projects in local medical insurance, and commercial health insurance pilot programs cover early screening products, significantly reducing the payment threshold for patients and effectively releasing market demand for early screening both in hospitals and outpatients. Pharmaceutical companies and diagnostic companies are deeply integrated to jointly develop companion diagnostic products for targeted drugs, achieving "drug testing in sync". This promotes testing as a pre-treatment step in clinical medication, opens up space for large-scale sales within hospitals, and patients' awareness and acceptance of non-invasive screening and precision diagnosis and treatment continue to improve. The high compliance of non-invasive blood collection further activates C-end demand. Multiple factors are driving the rapid expansion of the market.

DIResearch provides market research reports, focus on market segmentation research, industry research, market status and forecasts, players competition analysis, company positioning, downstream customer and product market analysis, etc. We effectively analyze complex data and information through professional methods, and finally present the research content of customer needs in the form of reports, helping companies make more valuable business decisions, helping companies improve operational efficiency and find new growth points.